Precursor Cell Lymphoblastic Leukemia-lymphoma
📧 Sign up to get email alerts when something new happens for Precursor Cell Lymphoblastic Leukemia-lymphoma.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2023-12-07EMA Withdrawn: Ivozall (clofarabine) — ORPHELIA Pharma
EMA has withdrawn Ivozall (clofarabine) from the market for the therapeutic area of precursor cell lymphoblastic leukemia-lymphoma.
-
EMA withdrawal · 2023-10-19EMA Withdrawn: Imatinib Koanaa (imatinib mesilate) — Koanaa Healthcare GmbH
The EMA status shows Imatinib Koanaa (imatinib mesilate) has been withdrawn from the market by Koanaa Healthcare GmbH.
-
EMA withdrawal · 2023-03-30EMA Withdrawn: Dasatinib Accordpharma (dasatinib) — Accord Healthcare S.L.U.
The EMA has withdrawn the dasatinib product Accordpharma from Accord Healthcare S.L.U. for indications including precursor cell lymphoblasti…
-
EMA withdrawal · 2023-03-30EMA Withdrawn: Dasatinib Accord (dasatinib) — Accord Healthcare S.L.U.
The EMA has withdrawn the Dasatinib Accord product (dasatinib) from Accord Healthcare S.L.U., applicable to precursor cell lymphoblastic leu…
-
EMA withdrawal · 2019-10-16EMA Withdrawn: Imatinib medac (imatinib) — Medac
The EMA has withdrawn Imatinib Medac (imatinib) from the market.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2019-01-23EMA Application withdrawn: Graspa (asparaginase) — ERYTECH Pharma S.A.
EMA withdrawal of Graspa (asparaginase) application for Precursor Cell Lymphoblastic Leukemia-Lymphoma.
-
EMA withdrawal · 2017-04-25EMA Application withdrawn: Graspa — ERYTECH Pharma S.A.
EMA has withdrawn the application for Graspa by ERYTECH Pharma S.A., in the therapeutic area of Precursor Cell Lymphoblastic Leukemia-Lympho…